Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04052555
Title Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Mayo Clinic Hospital in Arizona Phoenix Arizona 85054 United States Details
Mayo Clinic in Arizona Scottsdale Arizona 85259 United States Details
University of California Davis Comprehensive Cancer Center Sacramento California 95817 United States Details
Mayo Clinic in Florida Jacksonville Florida 32224-9980 United States Details
Mayo Clinic in Rochester Rochester Minnesota 55905 United States Details
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903 United States Details
NYP/Weill Cornell Medical Center New York New York 10065 United States Details
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210 United States Details
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh Pennsylvania 15232 United States Details
University of Texas Medical Branch Galveston Texas 77555-0565 United States Details
Farmington Health Center Farmington Utah 84025 United States Details
University of Utah Sugarhouse Health Center Salt Lake City Utah 84106 United States Details
Huntsman Cancer Institute/University of Utah Salt Lake City Utah 84112 United States Details
University of Wisconsin Carbone Cancer Center Madison Wisconsin 53792 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field